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healing at doses comparable to those tolerated in patients. A
clinical trial on the use of PTH (1–34) to stimulate distal radial
fracture healing is currently in progress.
3. Statins
Statins (HMG-CoA reductase inhibitors) are lipid-lowering
drugs that inhibit cholesterol synthesis by blocking meval-
onic acid production. Mevalonic acid is a precursor for both
cholesterol and geranyl geranyl pyrophosphate (GGPP).Multi-
ple intracellular pathways in osteoclast depend on the actions
of GGPP, including those involved in maturation. By block-
ing these pathways, fracture repair may proceed through
increased bone formation secondary to a decrease in bone
turnover. In addition, statins have been shown to induce the
BMP promoter in bone cells.
Oral simvastatin use has been shown to increase bone min-
eral density in several human studies and subsequent animal
studies have supported these results. With regards to fracture
healing, Skoglund et al. tested simvastatin in a mouse model
of femur fractures. They produced internally stabilised femur
fractures in 81 mature BALB/c mice. Half of these mice then
received a daily oral dose of 120mg/kg of simvastatin for up
to 21 days. Their results showed that at day 14, the mechani-
cal strength of the simvastatin group was 64% greater than in
the control mice and the callus was 53% larger. Whilst their
study did not ﬁnd a continuation of these trends at 21 days,
their study demonstrated that simvastatin could be effecting
in accelerating the healing process.
The statins currently in use target the liver, and much of
the drug is metabolised (ﬁrst pass effect) and not available
for action in bone. For this reason, systemic use of statins
to target bone will require further development. In a study
to test the local application of a statin, Garrett et al. com-
bined lovastatin with biodegradable polymer nanobeads of
poly(lactic-co-glycolide acid) and injected this mixture into
femur fractures in rats. At 4 weeks, they noticed a decrease in
the fracture gap as measured by microcomputed tomography.
Clinical trials are necessary to determine if these studies will
translate into clinically signiﬁcant gains in fracture healing.
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Osteosynthesis of pilon fractures: Tips and tricks
H. Zwipp
Unfallkrankenhaus Berlin, Germany
Pilon fractures are some of the most demanding fractures of the
skeleton especially C-type fractures with additional severe soft tis-
sue injury. Our concept of operative treatment is related to both the
fracture type and the soft tissue damage. If possible B-fractures are
treated by arthroscopy and ﬂuoroscopy with reduction and percu-
taneous screw ﬁxation or anterior buttressing using small plates.
If soft tissues allow C1- and C2-fractures are treated with the AO
pilon plate, through an open anterior or medial approach. In C-type
fractures (43.C1–C3) with signiﬁcant soft tissue damage, a 2-stage
procedure with primary tibio-tarsal transﬁxation should always
be performed. After 10–12 days, secondary ﬁbula and tibia recon-
struction should be performed and ﬁxated with a pilon plate. In
cases of types II/III fractures with severe closed soft tissue injuries,
according to Tscherne, treatment should include minimally inva-
sive open reduction through limited approaches or arthroscopy
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ombined with ﬂuoroscopy. The fracture, would than be ﬁxated
y screws just for the joint block, combined with a hybrid ﬁxator.
n second and third degree open fractures a 2–3 stage procedure
ncluding local and free ﬂap coverage is recommended. No infec-
ions, no nonunions and a very low rate of posttraumatic arthritis
11 versus 45 ORIF cases)1 were seen in a small series with this
inimal-invasive procedure combined with the use of a hybrid
xator.
eference
1 Endres, et al. Unfallchirurg 2004;4:161–78.
oi:10.1016/j.injury.2009.06.208
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rthopaedic trauma research priority setting exercise and
evelopment of a research network
. Willett a, B. Graya,∗, C. Morand, P. Giannoudisb, I. Pallister c
University of Oxford, UK
University of Leeds, UK
Swansea University, UK
University of Nottingham, UK
ackground: TheUKorthopaedic trauma community recognises the
mportance of clinically relevant trials that have high utility and the
otential to inﬂuence practice. Surgical trials are inherently difﬁ-
ult with problems around clinical equipoise, surgeon preference
nd participant acceptability, particularly comparing operative and
on-operative treatments. Research activity can be maximised by
ollaboration in (a) the identiﬁcation of important research ques-
ions and (b) involvement in clinical trials.
ethods: A Delphi survey was used to identify and prioritise the
esearch questions felt to be of most importance and to determine
onsensus between the facultymembers of the AOUK. A two-round
rocess was used to elicit the research questions and then to rank
hem in order of priority.
esults: 255 members of the AOUK faculty were contacted to iden-
ify areas of contemporary practice that they considered needed
uality research. 49 responders (19%) generated 147 questions.
hese were collated and the most frequently occurring questions
24) sent back out to all 255 for ranking by median scores. 121
47%) responded to this second round and prioritised 10 clinical
esearch questions. Literature searches for these 10 considered cur-
ent knowledge of the subject. In addition, completed and ongoing
esearch projects, advantages and disadvantages of undertaking a
tudy and themost appropriatemethodologywere also considered.
eedback on the outcome of this exercise was reported to the fac-
lty and a Research Conference planned to provide the opportunity
or individuals to become involved, for current research projects to
nd support and new research projects to be developed.
onclusion: The Delphi technique successfully prioritised research
uestions of importance to the AOUK membership, demonstrating
n interest in developing a collaborative research strategy. Inter-
sted individuals and the level atwhich theymight contributewere
lso identiﬁed,with a raised awareness of how toutilise the support
f the national research networks.
eywords: Delphi process; Research; Priority setting; Orthopaedic
rauma
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Payment by results (PbR) in orthopaedic trauma: Where are we
losing?
N.S. Harshavardhanab, A. Sahuc,∗, S. Maretd, A. Sangara, P. Jairaj a,
S.W. Richardsa
a Poole General Hospital NHS Trust, UK
b Nottingham University Hospitals NHS Trust, UK
c Stepping Hill Hospital, UK
d Southampton University Hospitals NHS Trust, UK
Background: Clinical coding has attracted signiﬁcant interest
recently as it has become synonymous with reimbursement. We
herebypresent the results of ﬁrst and largest study in theUK involv-
ing 547 orthopaedic trauma cases wherein a meticulous in-depth
analysis was performed.
Study design: Completed audit cycle.
Objectives: To review the existing coding for orthopaedic trauma, to
ascertain accuracy of procedural codes and to identify limitations,
implement changes, re-evaluate and close the audit loop.
Methods: All orthopaedic trauma surgeries (244 cases) performed
over 1 month (March 2006) were comprehensively analysed.
The primary procedural accuracy of OPCS4.2, its limitations
and loss of revenue due to missing codes (6 patients) were
determined. Changes were implemented to streamline/optimise
ﬁnancial reimbursement and improve data quality/accuracy by
education/training. Electronic discharge summaries were imple-
mented to enhance efﬁciency. The audit loop was subsequently
closed to evaluate implementation of these changes by re-
auditing all trauma surgeries performed in the same month
the following year, i.e. March 2007 (303 cases) against OPCS4.3
codes.
Results: The primary procedural accuracy was 95.38% (11/238
coding errors) andomissions in6patients resulted innet loss of rev-
enue of £13,700 forMarch 2006. Following the closure of audit loop
in March 2007 after implementation of changes, the primary pro-
cedural accuracy was 98.95% (3/286 coding errors) and cumulative
loss of revenue due to omissions in 17 patients was £46,750.
Discussion: Despite improvement in coding accuracy to 99% on clo-
sure of audit loop, there were increased ﬁnancial losses for trauma
directorate. An in-depth analysis is being performed to identify
lacunae (training/stafﬁng issues) as the trauma workload rose by
25% in a year.
Conclusion: Accurate and ethical coding is challenging having
impact on data quality, audit and research in addition to reimburse-
ment. Literature emphasises on legible documentation, liaison
between coders and clinicians and education/training of healthcare
professionals.
Keywords: Clinical coding; Payment by results (PbR); OPCS codes;
Data quality
doi:10.1016/j.injury.2009.06.210
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A practical VTE risk assessment score tool for patients treated
with lower limb cast immobilization
J. Keenan, M.J. Hall ∗, T.J.C. Nokes
Derriford Hospital, UK
Wehave devised a uniqueVTE risk assessment score for patients
treated with lower limb cast immobilisation.
The patient’s VTE risk factors have weighted scores dependent
on the severity of risk. The resulting overall score decides whether
thepatient is commencedonLMWHornot. The reliabilityof the risk
